Natera (NTRA) Expected to Announce Quarterly Earnings on Thursday

Natera (NASDAQ:NTRA) is projected to issue its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $447.91 million for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Natera Stock Down 1.5 %

NTRA stock opened at $156.00 on Wednesday. The company has a fifty day moving average price of $167.49 and a 200 day moving average price of $146.50. Natera has a 12 month low of $70.71 and a 12 month high of $183.00. The company has a market cap of $20.60 billion, a price-to-earnings ratio of -88.64 and a beta of 1.66. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23.

Insider Buying and Selling at Natera

In other Natera news, CEO Steven Leonard Chapman sold 78,553 shares of the company’s stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $12,958,888.41. Following the sale, the chief executive officer now owns 267,629 shares of the company’s stock, valued at $44,150,756.13. This represents a 22.69 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John Fesko sold 663 shares of the company’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $177.77, for a total transaction of $117,861.51. Following the completion of the sale, the insider now directly owns 156,044 shares in the company, valued at $27,739,941.88. This trade represents a 0.42 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 295,772 shares of company stock worth $49,741,699. 7.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

NTRA has been the subject of several research reports. Canaccord Genuity Group upped their price target on shares of Natera from $165.00 to $180.00 and gave the company a “buy” rating in a research report on Friday, January 3rd. StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. The Goldman Sachs Group boosted their price objective on shares of Natera from $160.00 to $190.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. Piper Sandler boosted their price objective on shares of Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a research note on Monday, November 18th. Finally, Sanford C. Bernstein boosted their price objective on shares of Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, January 10th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $170.94.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.